🇺🇸

Regulatory Compliance

US SEC Filing Intelligence · 158 digests

· daily

US SEC Trading Suspension Halt Orders — October 30, 2026

A wave of listing-standard deficiencies hit US exchanges on October 30, 2026, with 8 of 9 filings tied to trading suspensions, delistings, or regulatory halts. The dominant theme is the $1.00 minimum bid price rule: Alset, Actuate Therapeutics, Neumora, and Bridger Aerospace all received Nasdaq notices on October 26-28, each with an April 26, 2027 cure deadline, while Annovis Bio and Accendra Health (formerly Owens & Minor) face NYSE market-cap/equity deficiencies. Banzai International disclosed a delisting notice alongside a massive charter amendment increasing authorized shares to 850 million, signaling a likely reverse-split or restructuring path. Cyngn Inc. faces a Nasdaq audit committee composition breach after a director resignation, and Game Your Game Inc. filed a director appointment with a delisting flag in its header but no substantive delisting details. The clustering of bid-price notices suggests a broad small-cap valuation compression, with multiple companies signaling reverse stock splits as the primary cure mechanism. Investors should brace for a wave of reverse splits and potential delistings in late 2026 and early 2027, with April 26, 2027 emerging as a critical compliance cliff.

9 high priority 9 total filings
· daily

US SEC Trading Suspension Halt Orders — October 29, 2026

The October 29, 2026 US trading-suspension stream is dominated by listing-standard stress: three of four filings involve Nasdaq compliance failures or delistings, while one is a voluntary NYSE-to-TXSE transfer. The most acute events are Glucotrack's confirmed delisting (trading suspended at the open on October 30, 2026) and Propanc Biopharma's imminent delisting (effective November 2, 2026 absent an appeal by October 30, 2026), both driven by the $1.00 minimum bid price rule and complicated by prior reverse splits. Greenland Energy Company (Pelican Holdco) remains listed but has an outstanding majority-independent-director deficiency with a cure period running to the earlier of its next annual meeting or October 20, 2027, though its audit committee deficiency was cured on October 27, 2026. Cullen/Frost's move is fundamentally different: a board-authorized, voluntary transfer of both its common and Series B preferred listings to the Texas Stock Exchange, with NYSE trading ending November 11 and TXSE trading beginning November 12, 2026, under the same symbols. Across the stream, the common thread is exchange-listing risk management: micro-caps face forced delisting and OTC migration, while a large Texas bank is opting into a regional exchange for strategic reasons. Near-term catalysts are concentrated in the next 72 hours (Glucotrack suspension, Propanc appeal deadline) and the next two weeks (Cullen/Frost listing transition).

4 high priority 4 total filings
· daily

US SEC Trading Suspension Halt Orders — October 28, 2026

Both filings in this stream concern Nasdaq listing-compliance actions tied to sub-$1.00 share prices, which places them squarely within the Trading Suspension, Delisting, and Regulatory Halt scope. OSR Health (formerly OSR Holdings) is the more advanced case: Nasdaq trading has been suspended since August 26, 2026, the Hearings Panel has denied continued listing as of October 23, 2026, and the securities now trade OTC while the company evaluates options with an update promised by November 6, 2026. Milestone Pharmaceuticals is at an earlier stage, having received a Nasdaq deficiency letter on October 23, 2026 with a compliance deadline of April 21, 2027, and no present impact on its listing. The common thread is a bid-price problem that management has not solved through reverse splits in OSR's case, while Milestone retains the 180-day cure window and a possible transfer to the Nasdaq Capital Market. Both situations carry negative sentiment, with OSR rated more material (8/10) than Milestone (6/10). Enriched period-over-period financial metrics, insider activity, and capital allocation data were not supplied for either filing, so the quantitative read is limited to disclosed dates, deadlines, and terms rather than trend analysis. The practical implication is that trading-suspension and delisting risk is now concentrated in a single name already off Nasdaq, with a near-term catalyst date and a clear forced-decision point for the other.

2 high priority 2 total filings
· daily

US SEC Trading Suspension Halt Orders — October 27, 2026

Five filings dated 2026-10-27 span Nasdaq listing-compliance actions and one voluntary exchange migration, all within the trading suspension, delisting, and regulatory halt scope. The dominant theme is sub-$1.00 bid price and minimum-value deficiencies forcing small-cap issuers toward delisting or compliance extensions: Rekor Systems received a 180-day extension to April 26, 2027, Advasa Holdings faces an April 19, 2027 deadline after 30 consecutive business days below $1.00, and NextNRG is in the most severe position, with a delisting determination already issued and a Nasdaq Hearings Panel decision pending after an October 22, 2026 hearing. Socket Mobile is leaving Nasdaq Capital Market voluntarily for OTCID, with last Nasdaq trading expected November 18, 2026 and OTCID quotation starting around November 19, 2026, citing a stockholders' equity shortfall flagged August 24, 2026. The filings contain limited period-over-period financial data, so trend quantification is restricted to listing-standard thresholds and dated compliance timelines rather than revenue or margin comparisons. General Motors' bylaw amendment is governance-only and largely immaterial to the suspension and delisting theme.

5 high priority 5 total filings
· daily

US SEC Trading Suspension Halt Orders — October 26, 2026

Three SEC 8-K filings dated around October 21-26, 2026 touch on US listing-status events: Elme Communities' NYSE delisting tied to a Plan of Sale and Liquidation, Zeo Energy's Nasdaq bid-price compliance extension, and Eve Holding's NYSE suspension and delisting of its public warrants for an abnormally low selling price. All three are within the stream's focus (trading suspensions, delistings, regulatory halts on US exchanges), so none are excluded. The filings supplied do not include period-over-period financial figures, insider transactions, capital allocation amounts, or forward-looking financial guidance, so the quantitative synthesis is limited and the analysis rests mainly on qualitative event data and dates. The dominant theme is that two of three events are exchange-driven listing-status changes rather than operating news, with Elme being a voluntary wind-down and Eve and Zeo being price-related listing deficiencies. Investors should treat the Elme event as the most material (8/10) because it removes the common shares from a major exchange and is contingent on a liquidating trust process, while Zeo and Eve carry lower near-term market impact but flag persistent share-price weakness.

3 high priority 3 total filings
· daily

US SEC Trading Suspension Halt Orders — October 23, 2026

All nine filings in this USA Trading Suspensions stream are Nasdaq or NYSE listing-compliance notices, not trading suspensions, delistings actually executed, or regulatory halts; they are best read as a cluster of distressed micro- and small-cap issuers approaching or past exchange cure deadlines. The dominant theme is stockholders' equity and minimum bid price deficiencies: Lunai Bioworks is voluntarily delisting with suspension expected October 30, 2026, Dragonfly Energy has until December 31, 2026 to evidence equity compliance, and Polar Power claims it has regained compliance using insider-driven conversions and dilutive financings. Bid-price deficiencies cluster around April 19-21, 2027 deadlines for Akebia, Laser Photonics, Century Casinos (MVLS), and Innventure, while Medicus Pharma cured its bid price on October 23, 2026 after a delisting determination. Enriched period-over-period comparison fields were not populated in the provided summaries, so quantitative trend claims are limited to balance-sheet snapshots (e.g., Lunai deficit of $(9.02)M, Dragonfly deficit of $(184)K) rather than YoY/QoQ growth or margin trends. Portfolio-level implication: near-term event risk is concentrated in Lunai's October 30 suspension and Polar's October 28 compliance-evidencing filing, with the rest a slower-burning 2026-2027 delisting pipeline.

9 high priority 9 total filings
· daily

US SEC Trading Suspension Halt Orders — October 22, 2026

The USA Trading Suspensions stream for October 22, 2026 contains three Nasdaq-related 8-K filings, all centered on listing-compliance failures rather than trading halts themselves. Atlantic American (AAME) faces the most immediate risk: it must request a Hearings Panel review by October 23, 2026 to avoid suspension after a 15-day automatic stay, following a delinquent-filing delisting determination. Alaunos Therapeutics (ALT) is mid-remediation, claiming restoration of the $2.5 million stockholders' equity requirement via a ~$350.0 million private placement and the Velaris merger, but its November 10, 2026 Panel hearing and FY2026 10-K filing will determine whether the cure holds. SenesTech (SNES) has a longer runway, receiving a minimum bid price deficiency notice with a compliance deadline of April 19, 2027. Period-over-period financial comparisons are largely absent from these filings, so quantitative trend analysis is limited; the enriched data shows no revenue, margin, insider, or capital-allocation changes for the three companies. The common theme is that delinquent reporting, sub-$1 pricing, and equity shortfalls are the triggers for Nasdaq enforcement, making monitoring of exchange notices more predictive than financial ratios in this stream.

3 high priority 3 total filings
· daily

US SEC Trading Suspension Halt Orders — October 21, 2026

This stream contains a single filing, an 8-K from Direct Digital Holdings (DRCT), which falls squarely within the Trading Suspension/Delisting scope. The company received a Nasdaq delist determination on October 1, 2026 under Listing Rule 5550(b)(1), has been trading-suspended since October 5, 2026, and now intends to voluntarily withdraw its Class A common stock from listing and Section 12(b) registration. The filing describes a managed exit: Form 25 around November 2, 2026, delisting effective about November 12, 2026, Section 12(b) termination about January 31, 2027, followed by a Form 15 deregistration under Section 12(g). Shares will move to OTC Pink Limited Information with no assurance of a continuing market. The company cites going-concern doubt and credit-facility covenant risk, and says it lacked sufficient grounds to appeal and found continued SEC reporting too costly. Enriched period-over-period, insider, guidance, and capital allocation fields are not populated in this filing, so cross-company comparisons and quantitative trend analysis are not possible from this stream. The market implication is clearly negative: loss of exchange liquidity, reduced disclosure, and heightened solvency risk.

1 high priority 1 total filings
· daily

US SEC Trading Suspension Halt Orders — October 20, 2026

Four 8-K filings from the USA Trading Suspensions stream (period 2026-10-20) cover a mix of listing-compliance stress and a voluntary exchange move. Lottery.com (SEGG/LTRYW) faces the most acute event: a missed Q2 2026 10-Q has triggered a Nasdaq suspension that would begin October 23, 2026 absent a Panel hearing, which the company has requested and which stays suspension for 15 days. SHF Holdings and XWELL both face bid-price deficiencies but with runway, to April 19, 2027 and April 5, 2027 respectively, and neither faces an immediate trading halt. Hilton's transfer from NYSE to Nasdaq (effective November 5, 2026, same ticker HLT) is administrative and not a delisting. The enriched period-over-period, insider, capital allocation, and financial ratio fields are not populated in these filings, so quantitative trend comparisons across companies cannot be made; conclusions rest on filing-stated dates and events. The common theme is Nasdaq enforcement of timeliness and minimum-price standards, with the Lottery.com case the only one with a near-term suspension date.

4 high priority 4 total filings
· daily

US SEC Trading Suspension Halt Orders — October 19, 2026

The USA Trading Suspensions stream for 2026-10-19 contains two filings, and only one is squarely in scope. Stardust Power (SDST) is the core event: a Nasdaq Staff Determination triggered by ten consecutive trading days at or below $0.10 mandates suspension and delisting of both common stock and warrants at the open on October 23, 2026, with a hearing request (fee $20,000, deadline 4:00 p.m. ET October 23) that will not stay the suspension. Compounding the event are the CFO's resignation effective October 23, a board exploring headcount cuts, possible suspension of SEC reporting, and strategic alternatives with no assurance of success. Scienture Holdings (8-K) is a mixed-sentiment filing: preliminary unaudited Q3 2026 revenue of about $1.22 million rose 256% from roughly $344,000 in Q2 2026 on the REZENOPY launch and Arbli wholesale unit growth of 74% sequentially, but it carries going-concern language and an explicit Nasdaq listing risk under Item 3.01, so it sits adjacent to the delisting theme rather than as a completed event. Enriched period-over-period data for Stardust is limited to the compliance-deadline timeline rather than financial trends, and the market value of listed securities deficiency (April 24, 2026 notice, October 21, 2026 deadline) shows the company was failing multiple Nasdaq standards before the bid-price trigger. Overall the stream's theme is listing-standard failure leading to forced delisting, with the Scienture revenue inflection being the one counter-signal, though preliminary and unaudited.

2 high priority 2 total filings
· daily

US SEC Trading Suspension Halt Orders — October 16, 2026

Across the nine filings in the USA Trading Suspensions stream, the dominant theme is Nasdaq and NYSE listing-compliance stress rather than outright trading halts: five companies (eHealth, Lucid Diagnostics, Health In Tech, Bridgeline Digital, Canopy Growth) received $1.00 minimum bid price deficiency notices, all with an April 12, 2027 compliance deadline, and Callan JMB faces a hard suspension date of October 21, 2026 absent a successful hearing. A second cluster is voluntary or sponsor-driven delisting: SITE Centers (Form 25 targeted November 23, 2026, trading ends before December 4) and Apollo Commercial Real Estate Finance (Form 25 around October 27, last NYSE trade November 6, no stated reason). Aether Holdings carries a governance deficiency (missed annual meeting) with a November 27, 2026 compliance-plan deadline. The filings contain little quantitative period-over-period financial data, so the signal is largely event-driven: the most time-critical items are Callan JMB's October 19 appeal deadline and October 21 suspension date, Canopy Growth's October 23 reconvened reverse-split vote, and the November wave of NYSE/Form 25 dates. Market implication: the reverse-split/bid-price cohort faces dilution and potential delisting risk, while the voluntary delistings are more event-driven and less indicative of distress.

9 high priority 9 total filings
· daily

US SEC Trading Suspension Halt Orders — October 15, 2026

This digest covers two Nasdaq minimum bid price deficiency notices, both issued in October 2026 to small-cap companies whose common stock has closed below $1.00 for 30 consecutive business days. Innovative Eyewear (LUCY) received its notice on October 9, 2026 with a compliance deadline of April 7, 2027, while Cyngn (CYN) received its notice on October 14, 2026 with a deadline of April 12, 2027. Both notices are formally non-disruptive to listing status today, but both companies face a 180-day window to regain compliance by closing at or above $1.00 for 10 consecutive business days. The filings provide no period-over-period financial comparisons, insider transaction data, capital allocation details, or quantified forward guidance, so the enriched-data signals available for quantitative analysis are limited. The common theme is that both companies are exposed to potential reverse stock split actions and, if they fail to cure, to delisting proceedings with a right to a Nasdaq Hearings Panel review. The sector read-across is that sub-$1 equity is a shared pressure point for these issuers, with event risk clustered in the first half of 2027.

2 high priority 2 total filings
· daily

US SEC Trading Suspension Halt Orders — October 14, 2026

Both filings in this window concern Nasdaq listing-compliance matters rather than SEC trading suspensions per se, but they fall within the stream's Delisting and Regulatory Halt scope. AMASS Brands received a Nasdaq notice on October 9, 2026 for 30 consecutive business days below $1.00 (Rule 5450(a)(1)), with a compliance deadline of April 7, 2027, and it also carries a separate market value deficiency with a January 19, 2027 deadline. Netcapital Inc. regained bid-price compliance on October 7, 2026 after 10 consecutive business days at or above $1.00, but remains non-compliant with Rule 5250(c)(1) for late FY2026 10-K and Q1 FY2027 10-Q filings, with a compliance plan due October 23, 2026. The Netcapital situation is the more severe governance story: its FY2022 through FY2025 financial statements were declared unreliable, its prior auditor resigned, and a re-audit of FY2022 through FY2026 is underway. Enriched period-over-period, insider, forward-looking, and capital-allocation fields were not populated for either filing, so quantitative trend analysis is not possible from this data. The dominant theme is that sub-$1 price and filing-delinquency issues are colliding, creating delisting pathways that investors should track against specific dates.

2 high priority 2 total filings
· daily

US SEC Trading Suspension Halt Orders — October 13, 2026

All four filings in this trading-suspension, delisting, and regulatory-halt stream are Nasdaq or NYSE listing-compliance actions dated around October 6-8, 2026, and every one falls squarely within scope. Two filings (ClearOne and Newton Golf) involve stockholders' equity deficiencies under Nasdaq Rule 5550(b)(1) with imminent suspension or delisting dates (October 15 and October 19, 2026), while Equus faces a sub-$1.00 price deficiency on the NYSE and CN Healthy Food Tech has received a Panel decision permitting continued listing under a one-year monitor. The filings provide no period-over-period financial metrics, guidance, insider transactions, or capital allocation data, so quantitative trend analysis is not possible from this set; the signals below rest on event timing and regulatory status. The dominant theme is that a fundamental capital/equity shortfall is driving the most acute delisting risk, with the two Nasdaq equity-deficiency cases carrying the highest materiality and nearest deadlines. Investors should treat the October 13-20 window as the critical catalyst period for this group.

4 high priority 4 total filings
· daily

US SEC Trading Suspension Halt Orders — October 09, 2026

All five filings in this stream are negative-sentiment regulatory notices concerning US listing compliance rather than trading halts themselves: four involve Nasdaq or NYSE/NYSE American deficiency or delisting notices (minimum bid price, stockholders' equity, board governance, and late SEC filings), and none of the five has an immediate suspension in effect. The dominant theme is sub-$1.00 price and equity-deficiency pressure in small-cap issuers, with two companies (Streamex and Accendra Health) facing bid-price deadlines and one (Alaunos) facing an active delisting process that is stayed pending a Hearings Panel. Governance breakdown (Better Home & Finance) and reporting failure (IT Tech Packaging) show that non-price compliance failures are also driving exchange actions. The enriched fields for period-over-period financials, insider activity, forward-looking guidance, and capital allocation are largely absent from these notices, so the analysis rests on the regulatory timelines and deadlines disclosed. Market implication: the clearest near-term risk events are the Alaunos hearing and the Better Home compliance-plan deadline, while the longer-dated deadlines (April 2027) mainly signal potential reverse splits and dilution.

5 high priority 5 total filings
· daily

US SEC Trading Suspension Halt Orders — October 06, 2026

The USA Trading Suspensions stream for October 6, 2026, is dominated by three distinct Nasdaq listing actions, reflecting a bifurcated market: two companies (FibroGen/Kyntra Bio and Virtuix) face involuntary delisting due to failure to meet continued listing standards, while one (International Bancshares) voluntarily departs for a regional exchange. The involuntary delistings highlight a trend of small-cap distress, with both companies failing the $50M total assets/revenue alternative standard, and both are pursuing hearings or compliance periods to maintain their listings. Sentiment is negative for the two distressed companies (materiality 9/10 and 8/10), while the voluntary transfer is neutral (materiality 5/10), indicating no financial distress. Key forward-looking catalysts include Nasdaq Hearings Panel decisions (FibroGen) and a compliance deadline of March 29, 2027 (Virtuix), while IBOC's TXSE listing begins October 19, 2026. No insider trading or capital allocation data was provided in the enriched filings, limiting insights in those areas. The pattern suggests a regulatory environment where Nasdaq is actively enforcing listing standards, potentially creating trading opportunities in distressed securities and a shift toward alternative exchanges.

3 high priority 3 total filings
· daily

US SEC Trading Suspension Halt Orders — October 05, 2026

This digest covers three US trading suspension events on October 5, 2026, revealing a bifurcated market: two companies face involuntary delisting due to market capitalization failures, while one voluntarily migrates to a new exchange. ESS Tech (GWH) received a second NYSE delisting notice after failing to maintain a $15 million average market cap over 30 days, with trading suspended immediately—a severe bearish signal amplified by the lack of insider buying or capital allocation actions. Purple Innovation (PRPL) received a Nasdaq non-compliance notice for the same $15 million threshold, with a 180-day cure period, but no insider activity or financial data suggests a credible turnaround. CECO Environmental (CECO) voluntarily delisted from Nasdaq to join the Texas Stock Exchange (TXSE), a neutral strategic move that preserves liquidity. No period-over-period comparisons, insider transactions, forward-looking guidance, or capital allocation data were provided in any filing, limiting quantitative trend analysis. The key takeaway: micro-cap and distressed companies face heightened delisting risk under NYSE/Nasdaq minimum market cap rules, while exchange migration offers an alternative for firms seeking lower regulatory costs.

3 high priority 3 total filings
· daily

US SEC Trading Suspension Halt Orders — October 02, 2026

This digest covers 8 regulatory filings from October 2, 2026, all involving trading suspensions or delistings on US exchanges (NYSE American and Nasdaq). The dominant theme is a wave of micro-cap and pre-revenue companies failing to maintain minimum bid price or market value standards, with 6 of 8 filings triggered by sub-$1.00 bid prices. Notably, Healthcare Triangle faces an expedited delisting due to two reverse stock splits in two years, while Direct Digital Holdings and Amaze Holdings have already received final delisting notices with no appeal. The cluster of filings on September 28-29, 2026, suggests a coordinated exchange compliance review. No period-over-period financial data, insider activity, or capital allocation metrics were available in these filings, limiting quantitative trend analysis. The materiality is uniformly high (8-10/10), as delisting from a major exchange to OTC Pink or similar severely impairs liquidity and capital access. The key forward-looking dates cluster around March 29, 2027, for compliance deadlines, creating a catalyst calendar for investors to monitor.

8 high priority 8 total filings
· daily

US SEC Trading Suspension Halt Orders — October 01, 2026

The October 1, 2026 filings show a concentrated listing-status theme: one completed merger and Nasdaq delisting, one voluntary exchange transfer, two Nasdaq compliance notices, one NYSE suspension and OTC migration, and one board-composition deficiency. The most severe developments are Getty Images' immediate NYSE suspension and Lantern Pharma's failure to satisfy the $35 million minimum market value of listed securities requirement. Gaxos.ai faces a sub-$1.00 bid-price deficiency, while SKYX Platforms must rebuild its independent-board and audit-committee composition after the death of a director. NSTS Bancorp represents a completed liquidity event, with shareholders receiving $14.31 per share in cash and approximately $73.7 million in aggregate consideration. Nextdoor's move from NYSE to Nasdaq is operationally neutral but creates a defined October 14, 2026 trading catalyst. No filing supplied revenue, margin, earnings guidance, insider-trading, dividend, buyback, or valuation-comparison data; therefore, the actionable conclusions are driven primarily by regulatory status, cure periods, transaction terms, and trading-liquidity risk rather than operating-performance trends.

6 high priority 6 total filings
· daily

US SEC Trading Suspension Halt Orders — September 30, 2026

The two filings in this digest both involve US-listed companies facing imminent delisting actions from their primary exchanges, signaling a period of heightened regulatory and financial distress in the small/micro-cap biotech and clean-tech sectors. ESS Tech received a NYSE notice on September 24, 2026, for failing to meet the $50M stockholders' equity or market cap standard, while Outlook Therapeutics received a Nasdaq deficiency notice on September 25, 2026, for its sub-$1.00 bid price over 30 consecutive days. Both companies face negative sentiment and high materiality (9/10 and 8/10 respectively), with appeals and cure periods offering only uncertain paths to survival. The concentration of these events within a 24-hour window suggests a broader trend of exchange enforcement tightening on financially distressed issuers, potentially signaling a wave of delistings in the micro-cap space. Investors should monitor the appeal timelines and compliance deadlines closely, as failure to cure will lead to trading suspensions and potential OTCQB/OTCQX downgrades, impacting liquidity and valuation.

2 high priority 2 total filings